Andrea Necchi, Associate Professor at Università Vita-Salute San Raffaele, shared on X:
“Trastuzumab Deruxtecan (TDXd) is now available in Italy for patients with advanced HER2+ urothelial carcinoma who have exhausted standard therapies. This possibility comes a few weeks after EMA approval.”
Read also “HER2 in Urothelial Carcinoma: Biomarker Complexity and ADC-Based Treatment” on OncoDaily.
